Questions over dabigatran education for GPs

However, dabigatran sponsor Boehringer Ingelheim (BI) says the company has undertaken a wide-ranging education program to ensure appropriate patients and dosages are selected.

Last year the PBAC recommended dabigatran (Pradaxa) for PBS listing for an AF indication, but a decision has been delayed pending a review of all new anticoagulants.

In 2009 a landmark clinical trial found dabigatran was superior to warfarin at reducing rates of stroke and systemic embolism, with similar rates of haemorrhage .  

However, the editorial noted that the trial excluded many patients, including anyone with creatinine clearance <30 mL/min, active liver disease, valve disease, pregnancy, or any condition associated with increased
risk of bleeding.

“Randomised clinical trials by their inherent design enrol a safe and homogenised sample population, “the authors wrote, adding that it was not surprising that translating the